| Euroscore ii SAM Nashef, F Roques, LD Sharples, J Nilsson, C Smith, AR Goldstone, ... European journal of cardio-thoracic surgery 41 (4), 734-745, 2012 | 3144 | 2012 |
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ... The Lancet 377 (9783), 2103-2114, 2011 | 1268 | 2011 |
| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 816 | 2018 |
| Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ... Clinical Cancer Research 20 (20), 5322-5330, 2014 | 734 | 2014 |
| Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26. 2, 12q13. 13 and 20q13. 33 RS Houlston, J Cheadle, SE Dobbins, A Tenesa, AM Jones, K Howarth, ... Nature genetics 42 (11), 973-977, 2010 | 425 | 2010 |
| Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk MG Dunlop, SE Dobbins, SM Farrington, AM Jones, C Palles, N Whiffin, ... Nature genetics 44 (7), 770-776, 2012 | 279 | 2012 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 76 (6), 748-758, 2021 | 257 | 2021 |
| Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials JF Seligmann, D Fisher, CG Smith, SD Richman, F Elliott, S Brown, ... Annals of Oncology 28 (3), 562-568, 2017 | 176 | 2017 |
| Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients F Mouliere, R Mair, D Chandrananda, F Marass, CG Smith, J Su, J Morris, ... EMBO molecular medicine 10 (12), e9323, 2018 | 145 | 2018 |
| Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome JH Pruitt, MB Welborn, PD Edwards, TR Harward, JW Seeger, TD Martin, ... | 145 | 1996 |
| Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer D Gale, K Heider, A Ruiz-Valdepenas, S Hackinger, M Perry, G Marsico, ... Annals of oncology 33 (5), 500-510, 2022 | 142 | 2022 |
| A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer NA Al-Tassan, N Whiffin, FJ Hosking, C Palles, SM Farrington, ... Scientific reports 5 (1), 10442, 2015 | 141 | 2015 |
| ctDNA monitoring using patient-specific sequencing and integration of variant reads JCM Wan, K Heider, D Gale, S Murphy, E Fisher, F Mouliere, ... Science translational medicine 12 (548), eaaz8084, 2020 | 139 | 2020 |
| Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy±cetuximab CG Smith, D Fisher, B Claes, TS Maughan, S Idziaszczyk, G Peuteman, ... Clinical Cancer Research 19 (15), 4104-4113, 2013 | 130 | 2013 |
| Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer KM Patel, KE Van Der Vos, CG Smith, F Mouliere, D Tsui, J Morris, ... Scientific reports 7 (1), 5554, 2017 | 93 | 2017 |
| Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC … TS Maughan, R Adams, CG Smith, MT Seymour, RH Wilson, AM Meade, ... Journal of Clinical Oncology 28 (15_suppl), 3502-3502, 2010 | 88 | 2010 |
| Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors CG Smith, T Moser, F Mouliere, J Field-Rayner, M Eldridge, AL Riediger, ... Genome medicine 12, 1-17, 2020 | 85 | 2020 |
| Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models R Mair, F Mouliere, CG Smith, D Chandrananda, D Gale, F Marass, ... Cancer research 79 (1), 220-230, 2019 | 84 | 2019 |
| Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer H Rodriguez‐Broadbent, PJ Law, A Sud, K Palin, S Tuupanen, A Gylfe, ... International journal of cancer 140 (12), 2701-2708, 2017 | 84 | 2017 |
| 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial … T Maughan, RA Adams, CG Smith, MT Seymour, R Wilson, AM Meade, ... European Journal of Cancer Supplements 7 (3), 4-5, 2009 | 75 | 2009 |
Prof Richard S KaplanMRC Clinical Trials Unit at University College LondonVerified email at ucl.ac.uk
